Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.32 |
| ▸ | WNT3A | P56704 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861134 | 0.83 | PTGS2 (0.47) | PTGS2PTGS1PARP1NPC1CTNNB1 | |
| SCHEMBL4859405 | 0.81 | PTGS2 (0.48) | PTGS2PTGS1PARP1CTNNB1WNT3A | |
| SCHEMBL5576987 | 0.80 | PTGS1 (0.45) | PTGS2PTGS1PARP1CTNNB1WNT3A | |
| SCHEMBL5311603 | 0.79 | PTGS2 (0.47) | PTGS2PTGS1PARP1NPC1ALOX5 | |
| SCHEMBL5307876 | 0.77 | PTGS2 (0.45) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4860602 | 0.77 | PTGS2 (0.47) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4857154 | 0.77 | PTGS2 (0.47) | PTGS2PTGS1ALOX5 | |
| SCHEMBL4860657 | 0.76 | PTGS2 (0.41) | PTGS2PTGS1NPC1TTRCTNNB1 | |
| SCHEMBL4857484 | 0.76 | CTNNB1 (0.56) | NPC1CTNNB1WNT3APRKCI | |
| SCHEMBL4856564 | 0.75 | PTGS2 (0.45) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007052831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | REN, GLS, ATP6V1B1 | PTGS2 638/4885PTGS1 344/4885PARP1 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.